Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia

What Was Tested

The paper reports a study of DSIP (delta sleep-inducing peptide), published as a randomized controlled trial.

Delta sleep-inducing peptide (DSIP) is an endogenous peptide that crosses the blood-brain barrier, named after its association with natural sleep and enhanced electroencephalogram (EEG) delta rhythm.

The aims were to assess depth of anaesthesia using bispectral index (BIS), the EEG and heart rate variability (HRV), and to determine whether DSIP altered the symmetry of EEG between the left and right cerebral hemispheres.

Who Took Part

PubMed tags the participants as women only.

Twenty-four female ASA I or II patients gave written, informed consent to a protocol approved by their local research ethics committee.

How the Study Was Run

The design is described as randomized.

Because people in this DSIP (delta sleep-inducing peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Twelve were randomly assigned as controls to receive saline.

The first administration of DSIP was while awake and the second after induction of anaesthesia with propofol and maintenance with isoflurane.

BIS and EEG parameters were measured continuously using a bilateral electrode montage.

What Was Measured

The subject headings attached to it are Anesthetics, Inhalation, Delta Sleep-Inducing Peptide, Electroencephalography, Heart Rate and Isoflurane.

What This Means in Plain Language

The paper is a randomized study of DSIP (delta sleep-inducing peptide).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (European journal of anaesthesiology), a journal based in England.

More context: the DSIP (delta sleep-inducing peptide) compound page, all human trials.